1. Scrip
  2. >>Therapy Areas

Job Cuts As Polyphor Focuses On First-In-Class Anticancer

And Cystic Fibrosis Antibiotic

 
• By John Davis

Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.  

Map_Allschwil_Switzerland
• Source: Shutterstock

After a Phase III new antibiotic program disappointment last year, Allschwil, Switzerland-based Polyphor Ltd. is refocusing its research efforts on a potential first-in-class immuno-oncology compound, while becoming a leaner organization with the loss of around 17 positions.

With current funds, Polyphor’s cash runway will last until the end of the first quarter of 2021, executives at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer